brexucabtagene autoleucel
gilead sciences
['car t', 'zuma-3']
moffitt's dr. bijal shah presents new two-year follow-up data on zuma-3 study evaluating kte-x19, an anti-cd19 car t-cell therapy, in relapsed/refractory b-cell #all. check out the poster discussion today at #asco22. view abstract: 
The official account of Moffitt Cancer Center. Our mission: to contribute to the prevention and cure of cancer. For news and stories visit https://t.co/XaP6iv4q19.